Skip to content

Clinical trials

Nervous System Diseases trials in France with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Nervous System Diseases Phase: Not applicable Country / region: France Clear all

30 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20131
20172
20194
20207
20211
20223
20234
20246
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Recruiting9
Unknown status3
Terminated2
Active, not recruiting1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Pôle Saint Hélier5
Assistance Publique - Hôpitaux de Paris3
University Hospital, Bordeaux3
Institut National de la Santé Et de la Recherche Médicale, France2
REGEnLIFE SAS2
Centre Hospitalier Charles Perrens, Bordeaux1
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts1
Centre Hospitalier St Anne1
Centre Hospitalier Universitaire de Nice1
Centre d'Investigation Clinique et Technologique 8051

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Nervous System Diseases30
Central Nervous System Diseases6
Brain Diseases5
Multiple Sclerosis4
Cognitive Dysfunction3
Autoimmune Diseases of the Nervous System2
Dementia2
Demyelinating Diseases2
Immune System Diseases2
Mental Disorders2

Trials

Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.